Jade Ebbelaar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jade Ebbelaar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Agustin Enciso-Martinez
Oncode Institute and Department of Cell and Chemical Biology Leiden University Medical Center Leiden The Netherlands
1 shared publication - Ali Salanti
Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark
1 shared publication - Caroline Løppke
Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
1 shared publication Edwin van der Pol
Amsterdam UMC, University of Amsterdam Biomedical Engineering & Physics, Meibergdreef 9; Cancer Center Amsterdam, Imaging and Biomarkers University of Amsterdam Amsterdam the Netherlands
1 shared publication- Elena Ethel Vidal-Calvo
Centre for Translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark
1 shared publication Emma P. E. M. Boerrigter
Oncode Institute Department of Cell and Chemical Biology Leiden University Medical Center Leiden the Netherlands
1 shared publication
Latest Publications
- Open Access
- 17 June 2025
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 14 (6) , e70106
Targeting Oncofoetal Chondroitin Sulphate Allows Identification of Tumour‐Derived Extracellular Vesicles
Tumour‐derived extracellular vesicles (tdEVs) are widely studied for their contribution to tumour progression and metastasis. These studies are hampered by the lack of specific markers to identify the tdEVs. Here, we show that oncofoetal chondroitin sulphate, a malignancy‐associated glycosaminoglycan modification, is present on tdEVs and can be targeted by the malaria VAR2CSA protein or C9 antibody. Using a fluorescently labelled recombinant VAR2CSA protein, we identified EVs from cancer cells in vitro by super‐resolution fluorescence microscopy and flow cytometry, as well as in a proof‐of‐concept study using plasma samples from pancreatic adenocarcinoma patients. Thus, the binding of VAR2CSA offers a tool to identify tdEVs, and can be used to explore their function and biomarker potential in cancer.
- 17 June 2025
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 14 (6) , e70106
Open AccessTargeting Oncofoetal Chondroitin Sulphate Allows Identification of Tumour‐Derived Extracellular Vesicles
Tumour‐derived extracellular vesicles (tdEVs) are widely studied for their contribution to tumour progression and metastasis. These studies are hampered by the lack of specific markers to identify the tdEVs. Here, we show that oncofoetal chondroitin sulphate, a malignancy‐associated glycosaminoglycan modification, is present on tdEVs and can be targeted by the malaria VAR2CSA protein or C9 antibody. Using a fluorescently labelled recombinant VAR2CSA protein, we identified EVs from cancer cells in vitro by super‐resolution fluorescence microscopy and flow cytometry, as well as in a proof‐of‐concept study using plasma samples from pancreatic adenocarcinoma patients. Thus, the binding of VAR2CSA offers a tool to identify tdEVs, and can be used to explore their function and biomarker potential in cancer.